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Abstract 
 During treatment with sunitinib, dosage adjustment according to the monitored 
blood concentration of sunitinib and SU12662 is considered useful. On the other hand, 
the appearance of hand-foot skin reaction (HFSR) cannot be explained by blood sunitinib 
concentration alone. Although light exposure greatly affects skin disorders associated 
with medication use, the photodegradation of sunitinib has not been studied in detail. Here, 
we investigated the photodegradation products of sunitinib using LC-MS and examined 
cytotoxic activities using an MTT assay. N-desethyl sunitinib and sunitinib N-oxide were 
identified as photodegradation products, and their concentrations increased under 
irradiation in a time-dependent manner. Although the IC50 value of N-desethyl sunitinib 
in the HEK 293 cell line (11.6 µmol/L) was similar to that of sunitinib (8.6 µmol/L), the 
IC50 value of sunitinib N-oxide (121.9 µmol/L) was over 10 times higher than that of 
sunitinib. In addition, N-desethyl sunitinib and sunitinib N-oxide were found in blood 
obtained from a patient taking sunitinib (24.7 and 2.3 ng/mL, respectively). Because the 
appearance of adverse drug reactions associated with sunitinib can be reduced by using 
α-tocopherol nicotinate, which has a strong antioxidant effect, we believe that sunitinib 
N-oxide might strongly promote the development of HFSR. 
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Introduction 
 Sunitinib, a multi-targeted tyrosine kinase inhibitor, is used as a first-line drug 
treatment for metastatic renal cell carcinoma (RCC) and is considered to be one of the 
key drugs for treating RCC [1-3]. The antitumor activity of sunitinib depends on its 
concentration in the blood and, in a meta-analysis of clinical trials of patients taking 
sunitinib for metastatic RCC and gastrointestinal stromal tumor, patients with a high 
cumulative area under the concentration-time curve (AUCcum) of total sunitinib—
reflecting the total amount of sunitinib and SU12662, an active metabolite of sunitinib—
had a significantly longer time to tumor progression and overall survival [4]. In addition, 
some adverse drug reactions (ADRs) such as anorexia and fatigue were reported to be 
correlated with total sunitinib concentration, and the mean total sunitinib concentration is 
also reported to be higher in patients with bleeding events than in those without them [5]. 
Thus, during treatment with sunitinib, dosage adjustment according to the monitored 
concentration of sunitinib and SU12662 in blood is considered useful [6-9]. 
 Noda and colleagues [5] have also reported that some dose-limiting toxicities of 
sunitinib, such as hand-foot skin reaction (HFSR), hypertension, and blood toxicity, 
developed irrespective of the total sunitinib concentration. In addition, the frequency of 
HFSR is significantly higher in Japanese people, although there is no significant 
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difference in the blood concentration of sunitinib between Japanese and Western 
populations [3, 10]. Thus, the appearance of HFSR cannot be explained solely by a high 
blood concentration of sunitinib. 
 Although HFSR due to sunitinib has been considered to be caused mainly by 
damage to the capillary endothelium due to physical pressure and VEGF inhibition, the 
precise mechanisms remain unclear [11]. The causes of skin disorders linked to the use 
of various drugs have been studied, and several factors and mechanisms have been 
elucidated. As an example, light-dependent photosensitivity is reported to be caused by 
the interaction of an active substance generated by light exposure with constituent 
components in the body [12]. In addition, skin disorders linked to a new quinolone 
antibacterial agent are caused by photoreactive substances generated by exposure of a 
drug or its metabolites in the skin to light [13]. As mentioned above, light exposure has 
been considered to strongly promote the appearance of skin disorders associated with 
medications [14]. 
 Sunitinib and SU12662 have been reported to be converted from the Z form to 
the E form by photoinduced isomerization upon exposure to light in water [15]. On the 
other hand, because the sum of the E and Z forms after irradiation of sunitinib did not 
coincide with the original drug amount in that study, it is conceivable that other 
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photodegradation products are generated. However, photodegradation products other than 
the E/Z conversion have not been well studied. 
 Accordingly, in this study, we investigated the photodegradation products of 
sunitinib in detail and studied the possibility that ADRs, including HFSR, are caused by 
the photodegradation products of sunitinib. 
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Methods 
Materials 
 Sunitinib and sorafenib were purchased from LC Laboratories (Woburn, MA). 
Sunitinib N-oxide and N-desethyl sunitinib were purchased from Toronto Research 
Chemicals (Toronto, Canada). Cell Proliferation Kit I (MTT) was purchased from Roche 
Diagnostics GmbH (Mannheim, Germany). The human embryonic kidney cell line HEK 
293 was purchased from the Japanese Collection of Research Bioresources (JCRB) Cell 
Bank (Osaka, Japan). ISOLUTE SLE+ column and UV lamp (SYN185UV1) were 
purchased from Biotage Japan Ltd. (Tokyo, Japan) and Merck KGaA (Darmstadt, 
Germany), respectively. Culture reagents were purchased from Wako Pure Chemical 
Industries (Osaka, Japan). All other reagents were obtained from commercial sources, 
and those used for analysis were graded for high-performance liquid chromatography, 
liquid chromatography-mass spectrometry (LC-MS), or analytical use. 
 
Sample preparation 
 Sunitinib, sunitinib N-oxide, N-desethyl sunitinib, and sorafenib were dissolved 
in methanol and diluted to 1.0 mg/mL with methanol as stock solutions. Samples were 
stored in light-proof bottles at −20°C. 
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Analysis of the photodegradation products of sunitinib 
 Sunitinib stock solution was diluted to 500 ng/mL with 50% methanol and 
exposed to room or UV (185 nm) light at room temperature. Samples were collected 0, 
24, 48, and 72 h after the start of the irradiation and photodegradation products were 
detected and quantified using time-of-flight (TOF) MS. The structures of these products 
were determined using quadrupole MS/MS (qMS/MS). 
 
MTT assay 
 The HEK 293 cell line was cultured in a humidified 5% CO2 incubator at 37°C. 
The cells were seeded at 4 × 105 cells/well in a 24-well plate and cultured for 24 h in 
Dulbecco's Modified Eagle's medium (DMEM) containing FBS at 37°C, followed by 
incubation at 37°C for an additional 24 h in 900 µL/well of serum-free DMEM. Thereafter, 
100 μL of sunitinib, sunitinib N-oxide, and N-desethyl sunitinib at 0.1, 0.25, 1.0, 2.5, 10, 
25, 100, 250, 1000, and 2500 μmol/L in 0.1% DMSO or 100 μL of 0.1% DMSO as control 
were added for 72 h. Then, 100 μL of MTT solution was added to each well and the cells 
were incubated at 37°C for 4 h. After the addition of 1 mL of DMSO, the samples were 
allowed to stand at room temperature for 1 h and absorbance at 570 nm was measured. 
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Cell viability was calculated by determining the ratio of the absorbance to that of the 
control group. 
 
Clinical analysis 
 Blood samples (8 mL) were taken from a patient who received 37.5 mg/day 
sunitinib with a 2-week on/1-week off schedule 24 h after the last dose of sunitinib. The 
blood was centrifuged at 3,000 rpm for 5 min to separate the plasma. A mixture of 50 μL 
of plasma, 10 μL of 50% methanol or standard solution in 50% methanol, 10 μL of 100 
ng/mL sorafenib in methanol (as internal standard), and 130 μL of Milli-Q® water 
(Millipore, Temecula, CA) was applied into an ISOLUTE SLE+ column (400 μL 
capacity). The sample was eluted with 2 mL of ethyl acetate, and the eluate was 
evaporated to dryness under reduced pressure. The residue was dissolved in 50 μL of 50% 
methanol, and 10 μL was used for LC-qMS/MS analysis. This study was approved by the 
Gunma University Ethical Review Board for Medical Research Involving Human 
Subjects; the patient gave written informed consent prior to participating in the study. 
 
Mass spectrometric analysis 
Exploration of photodegradation products was performed using time-of-flight 
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mass spectrometry (TOF MS) on an LCT Premier™ XE (Waters, Milford, MA), with 
flow injection mode and in LC-TOF MS mode for quantification of the detected 
photodegradation products. MS analysis was performed using an electrospray ionization 
(ESI) source in positive ionization mode (W mode). Survey scans were acquired in the 
range of 100 to 1000 m/z. Instrument settings were as follows: capillary voltage, 3200 V; 
sample cone voltage, 30 V; desolvation temperature, 350°C; source temperature, 130°C; 
cone gas flow, 60 L/h; desolvation gas flow, 700 L/h; and aperture 1 voltage, 0 V. For 
quantification of the detected photodegradation products, LC was performed with an 
ACQUITY UPLC® system (Waters). An ACQUITY UPLC® BEH C18 column (2.1 mm 
× 50 mm, 1.7 μm) (Waters) was used as the LC column. The LC conditions were as 
follows: column temperature, 40°C; mobile phase, 0.1% formic acid in Milli-Q® water 
(A) and 0.1% formic acid in acetonitrile (B); flow rate, 0.3 mL/min; gradient program, 
5% to 35% B in 6 min, 35% to 95% B in 1 min, 95% B for 2 min, and 95% to 5% B in 1 
min. 
Tandem quadrupole MS was used to determine the structure of the 
photodegradation products in flow injection mode and analyze the concentration of 
sunitinib and its degradation products in the plasma in LC-MS/MS mode. XevoTQ 
(Waters) with ESI turbo spray in the positive ionization mode was used with the following 
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ionization parameters: capillary voltage, 3000 V; desolvation temperature, 500°C; source 
temperature, 150°C; desolvation gas flow, 1000 L/h; and cone gas flow, 50 L/h. The 
following transitions were monitored: 399/283 for sunitinib, 371/283 for N-desethyl 
sunitinib, 415/326 for sunitinib N-oxide, and 465/252 for sorafenib. Sample cone voltage 
and collision energy were 50 V and 22 V for sunitinib, 32 V and 24 V for N-desethyl 
sunitinib, and 24 V and 22 V for sunitinib N-oxide, respectively. For blood sample 
analysis, LC was performed with an ACQUITY UPLC® system (Waters). An ACQUITY 
UPLC® BEH C18 column (2.1 mm × 50 mm, 1.7 μm) (Waters) was used as the LC 
column. The LC conditions were as follows: column temperature, 40°C; mobile phase, 
0.1% formic acid in Milli-Q® water (A) and 0.1% formic acid in acetonitrile (B); flow 
rate, 0.5 mL/min; and gradient program, 5% to 35% B in 6 min, 35% to 95% B in 1 min, 
95% B for 2 min, and 95% to 5% B in 1 min. 
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Results 
Analysis of photodegradation products 
 In TOF MS analysis of sunitinib exposed to UV light for 72 h, two clear signals 
were found at m/z 415.213 and 371.189 (Fig. 1). In qMS/MS analysis, signals at m/z 326, 
283, and 255 were found as fragment ions of m/z 415.2. Because the pattern of these 
fragment ions coincided with that obtained from m/z 399.2 of sunitinib, a 
photodegradation product found as the m/z 415.2 ion was identified as a sunitinib oxide, 
which was generated by oxidation of the nitrogen atom side of sunitinib, to which two 
ethyl groups bind (Fig. 2). Similarly, clear signals at m/z 326, 283, and 255 were found 
as fragment ions of m/z 371.2, and a photodegradation product found as the m/z 371.2 
ion was identified as a deethylate of sunitinib that was generated by deethylation of the 
tertiary amine of sunitinib (Fig. 2). In addition, in LC-qMS/MS analysis, the retention 
times of the peaks of the photodegradation products m/z 415/326 and 371/283 were 
consistent with the retention times of sunitinib N-oxide (m/z 415/326) and N-desethyl 
sunitinib (m/z 371/283), respectively. Furthermore, the MS spectra of the fragment ions 
of m/z 415.2 and 371.2 in UV-irradiated samples were consistent with the fragment ion 
MS spectra of m/z 415.2 of sunitinib N-oxide and of m/z 371.2 of N-desethyl sunitinib 
(data not shown). 
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 The concentration of sunitinib decreased in a time-dependent manner up to 48 h 
in the UV-irradiated sample and rapidly decreased after 72 h (Fig. 3A). By contrast, 
sunitinib was only slightly decreased after irradiation with indoor light. Sunitinib N-oxide 
comprised 64.0% and 77.0% of the photodegradation products in the samples exposed to 
UV light for 48 and 72 h, respectively (Fig. 3B). 
 
Analysis of the cytotoxicity of the photodegradation products of sunitinib 
 The cytotoxicity of sunitinib and its photodegradation products N-desethyl 
sunitinib and sunitinib N-oxide was assessed by MTT assay. In contrast to N-desethyl 
sunitinib (IC50 value, 11.6 µmol/L), the IC50 value of sunitinib N-oxide was over 10 times 
higher than that of sunitinib in the HEK 293 cell line (121.9 and 8.6 µmol/L for sunitinib 
N-oxide and sunitinib, respectively) (Fig. 4). 
 
Blood concentrations of the photodegradation products of sunitinib 
 The concentrations of sunitinib, N-desethyl sunitinib, and sunitinib N-oxide in 
blood obtained from a patient taking sunitinib at trough were 79.9, 24.7, and 2.3 ng/mL, 
respectively (Fig. 5). 
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Discussion 
 The risk of developing HFSR, one of the dose-limiting toxicities of sunitinib, 
has not been correlated with the blood concentration of sunitinib, and so elucidation of 
the factors leading to the onset of HFSR is required. We focused on the skin reactions 
accompanying light irradiation, considered an important clinical problem for many 
medicines, and investigated the photodegradation products of sunitinib. We found for the 
first time that sunitinib N-oxide is generated by UV irradiation of sunitinib and that it is 
also present in the blood of a patient taking sunitinib. Although sunitinib N-oxide was 
found in plasma and urine as a micro-decomposition product in an in vivo rat study, its 
contribution to drug efficacy and adverse and pharmacological effects has not been 
studied [16]. 
 Recently, α-tocopherol nicotinate was reported to reduce the appearance of 
ADRs related to sunitinib [17]. The authors found that ADR was reduced due to the 
hydrogen peroxide trapping efficacy of α-tocopherol nicotinate. However, because α-
tocopherol nicotinate has a strong antioxidant effect, we believed that the ADRs of 
sunitinib could be suppressed via an antioxidant-mediated decrease in sunitinib N-oxide 
generation. Because we have not assessed the impact of sunitinib N-oxide on the 
appearance of HFSR, we need to fully explore the influence of sunitinib N-oxide in the 
 16 / 29 
human body and the relationship between sunitinib N-oxide level and HFSR onset in 
future research. 
 In an MTT assay, the cytotoxic activity of sunitinib N-oxide was found to be 
lower than that of sunitinib and N-desethyl sunitinib. These data suggested that the effect 
of sunitinib N-oxide on humans may be different from that of sunitinib and N-desethyl 
sunitinib. However, we could not rule out the possibility that the differences in 
intracellular uptake of each substance may have affected the MTT assay results, and we 
also did not evaluate the pharmacological effects of sunitinib N-oxide in detail. At least 
for this point, the effect on sunitinib N-oxide on ADRs remains to be clarified and requires 
further in-depth study. 
 In the analysis of sunitinib and sunitinib-related compounds using LC, the 
retention time of sunitinib N-oxide was very similar to that of sunitinib. Because they 
both have the same basic structure, it may be difficult to distinguish these compounds by 
UV detection and accurate long-term separation analysis is needed to separately quantify 
these compounds using a UV detector [18]. Because the activity of sunitinib and sunitinib 
N-oxide was indicated to be different in our study, we believe that LC-MS/MS but not 
LC-UV/Vis is suitable for the separate routine clinical analysis of sunitinib and sunitinib-
related compounds. 
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 In conclusion, we found that sunitinib N-oxide was generated by UV irradiation 
of sunitinib and could be detected in the blood of a patient taking sunitinib. Although the 
pharmacological effects of sunitinib were not clarified, we believe that sunitinib N-oxide 
might strongly affect the appearance of ADRs because it has been reported that the ADRs 
induced by sunitinib can be ameliorated by antioxidant treatment. We aim to study the 
distribution and pharmacological effects of sunitinib N-oxide and assess its influence on 
the development of ADRs of sunitinib. 
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Figure legends 
Fig. 1 TOF MS spectrum of sunitinib solution before and after UV irradiation. A: 
before irradiation. B: after 72-h irradiation. 
 
Fig. 2 Fragment ion MS spectrum of photodegradation products. 
 
Fig 3. Amount of photodegradation products and duration of light exposure. A: Change 
in the amount of sunitinib and the total photodegradation products detected. Closed, 
sunitinib (E); open, sunitinib (Z); hatched, degradation products. B: Change in the amount 
of each of the photodegradation products detected. Closed, N-desethyl sunitinib (E); open, 
N-desethyl sunitinib (Z); hatched, sunitinib N-oxide (E); dotted, sunitinib N-oxide (Z). 
 
Fig. 4 Cytotoxic activity of sunitinib, N-desethyl sunitinib, and sunitinib N-oxide. 
Closed circle, sunitinib; closed square, N-desethyl sunitinib; open circle, sunitinib N-
oxide. 
 
Fig. 5 Chromatogram of a clinical sample. A: m/z 399/283 (sunitinib); B: m/z 371/283 
(N-desethyl sunitinib); C: m/z 415/326 (sunitinib N-oxide); D: m/z 465/252 (sorafenib as 
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internal standard). 
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Fig. 1  
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Fig. 2  
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Fig. 3 
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Fig. 4 
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Fig. 5  
 
